Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) is 40.24% higher on its value in year-to-date trading and has touched a low of $17.38 and a high of $28.15 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The KNSA stock was last observed hovering at around $26.97 in the last trading session, with the day’s gains setting it 0.77%.
Currently trading at $27.74, the stock is 29.83% and 28.41% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.1 million and changing 2.86% at the moment leaves the stock 22.60% off its SMA200. KNSA registered 49.54% gain for a year compared to 6-month loss of 0.54%. The firm has a 50-day simple moving average (SMA 50) of $21.602 and a 200-day simple moving average (SMA200) of $22.626625.
The stock witnessed a 27.42% gain in the last 1 month and extending the period to 3 months gives it a 39.54%, and is 34.92% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.77% over the week and 6.28% over the month.
Kiniksa Pharmaceuticals International Plc (KNSA) has around 315 employees, a market worth around $2.02B and $481.17M in sales. Fwd P/E is 25.43. Profit margin for the company is -3.52%. Distance from 52-week low is 59.61% and -1.46% from its 52-week high. The company has generated returns on investments over the last 12 months (-3.64%).
with sales reaching $145.26M over the same period.The EPS is expected to grow by 205.93% this year, but quarterly earnings will post 41.81% year-over-year. Quarterly sales are estimated to grow 33.72% in year-over-year returns.
242.0 institutions hold shares in Kiniksa Pharmaceuticals International Plc (KNSA), with institutional investors hold 96.70% of the company’s shares. The shares outstanding are 42.16M, and float is at 40.47M with Short Float at 8.19%. Institutions hold 92.79% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 4.59 million shares valued at $85.72 million. The investor’s holdings represent 6.466 of the KNSA Shares outstanding. As of 2024-06-30, the second largest holder is FAIRMOUNT FUNDS MANAGEMENT LLC with 3.2 million shares valued at $59.83 million to account for 4.5136 of the shares outstanding. The other top investors are HHLR ADVISORS, LTD. which holds 3.14 million shares representing 4.4287 and valued at over $58.71 million, while BAKER BROS. ADVISORS LP holds 3.9692 of the shares totaling 2.82 million with a market value of $52.62 million.
Kiniksa Pharmaceuticals International Plc (KNSA) Insider Activity
The most recent transaction is an insider sale by Moat Ross, the company’s CHIEF COMMERCIAL OFFICER. SEC filings show that Moat Ross sold 64,035 shares of the company’s common stock on Apr 29 ’25 at a price of $25.21 per share for a total of $1.61 million. Following the sale, the insider now owns 9415.0 shares.
Kiniksa Pharmaceuticals International Plc disclosed in a document filed with the SEC on May 01 ’25 that Moat Ross (CHIEF COMMERCIAL OFFICER) sold a total of 23,234 shares of the company’s common stock. The trade occurred on May 01 ’25 and was made at $28.02 per share for $0.65 million. Following the transaction, the insider now directly holds 9415.0 shares of the KNSA stock.
Still, SEC filings show that on Apr 29 ’25, Ragosa Mark (CHIEF FINANCIAL OFFICER) disposed off 42,000 shares at an average price of $25.61 for $1.08 million. The insider now directly holds 27,009 shares of Kiniksa Pharmaceuticals International Plc (KNSA).
